Protective effects of metformin against myocardial ischemia‑reperfusion injury via AMPK‑dependent suppression of NOX4

Shi,Yan; Hou,Shu-Ai

doi:10.3892/mmr.2021.12351

Protective effects of metformin against myocardial ischemia‑reperfusion injury via AMPK‑dependent suppression of NOX4

Authors:
- Yan Shi
- Shu-Ai Hou
View Affiliations

Affiliations: Department of Critical Care Medicine, People's Hospital of Rizhao, Rizhao, Shandong 276800, P.R. China
Published online on: August 10, 2021 https://doi.org/10.3892/mmr.2021.12351
Article Number: 712
Copyright: © Shi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Numerous studies have demonstrated that metformin can reduce the incidence of myocardial infarction and improve the prognosis of patients. However, its specific mechanism has not been determined. Using a rat model of myocardial ischemia‑reperfusion injury (MIRI), it was observed that metformin significantly reduced infarct size, and decreased the levels of plasma lactate dehydrogenase and creatine kinase‑MB form. A TTC‑Evans blue staining was used to detect the infarct size and MTT assay was used to evaluate the cell viability. TUNEL assay was performed to evaluate apoptosis. Furthermore, 4‑hydroxynonenal was detected by immunohistochemical staining. mRNA expression levels were detected by reverse transcription‑quantitative PCR; protein expression levels were detected by immunoblotting. When treated with metformin, the number of TUNEL‑positive cells was significantly decreased. Reduced 4HNE immunoreactivity was observed in metformin‑treated rats as determined via immunohistochemistry. Furthermore, NADPH oxidase 4 (NOX4) was downregulated by metformin at both the mRNA and protein levels, and adenosine 5'‑monophosphate‑activated protein kinase (AMPK) phosphorylation was increased by metformin. In a primary myocardial hypoxia‑reoxygenation cell model, metformin increased the viability of cardiomyocytes and reduced the content of malondialdehyde. It was also found that metformin upregulated the phosphorylation of AMPK and decreased the expression of NOX4. Furthermore, pre‑treatment with AMPK inhibitor compound‑C could block the effect of metformin, indicated by increased NOX4 compared with metformin treatment alone. These results suggested that metformin was capable of reducing the oxidative stress injury induced by MIRI. In conclusion, the present study indicated that metformin activated AMPK to inhibit the expression of NOX4, leading to a decrease in myocardial oxidative damage and apoptosis, thus alleviating reperfusion injury.

View Figures

View References

1	Malakar AK, Choudhury D, Halder B, Paul P, Uddin A and Chakraborty S: A review on coronary artery disease, its risk factors, and therapeutics. J Cell Physiol. 234:16812–16823. 2019. View Article : Google Scholar : PubMed/NCBI
2	Monassier JP: Reperfusion injury in acute myocardial infarction. From bench to cath lab. Part I: Basic considerations. Arch Cardiovasc Dis. 101:491–500. 2008. View Article : Google Scholar : PubMed/NCBI
3	Yellon DM and Hausenloy DJ: Myocardial reperfusion injury. N Engl J Med. 357:1121–1135. 2007. View Article : Google Scholar : PubMed/NCBI
4	Sies H: Oxidative stress: A concept in redox biology and medicine. Redox Biol. 4:180–183. 2015. View Article : Google Scholar : PubMed/NCBI
5	Matsushima S, Tsutsui H and Sadoshima J: Physiological and pathological functions of NADPH oxidases during myocardial ischemia-reperfusion. Trends Cardiovasc Med. 24:202–205. 2014. View Article : Google Scholar : PubMed/NCBI
6	Braunersreuther V, Montecucco F, Asrih M, Pelli G, Galan K, Frias M, Burger F, Quinderé AL, Montessuit C, Krause KH, et al: Role of NADPH oxidase isoforms NOX1, NOX2 and NOX4 in myocardial ischemia/reperfusion injury. J Mol Cell Cardiol. 64:99–107. 2013. View Article : Google Scholar : PubMed/NCBI
7	Matsushima S, Kuroda J, Ago T, Zhai P, Ikeda Y, Oka S, Fong GH, Tian R and Sadoshima J: Broad suppression of NADPH oxidase activity exacerbates ischemia/reperfusion injury through inadvertent downregulation of HIF-1α and upregulation of PPARα. Circ Res. 112:315–325. 2013. View Article : Google Scholar : PubMed/NCBI
8	Russell RR III, Li J, Coven DL, Pypaert M, Zechner C, Palmeri M, Giordano FJ, Mu J, Birnbaum MJ and Young LH: AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest. 114:495–503. 2004. View Article : Google Scholar : PubMed/NCBI
9	Folmes CD, Wagg CS, Shen M, Clanachan AS, Tian R and Lopaschuk GD: Suppression of 5-AMP-activated protein kinase activity does not impair recovery of contractile function during reperfusion of ischemic hearts. Am J Physiol Heart Circ Physiol. 297:H313–H321. 2009. View Article : Google Scholar : PubMed/NCBI
10	Liu B, Clanachan AS, Schulz R and Lopaschuk GD: Cardiac efficiency is improved after ischemia by altering both the source and fate of protons. Circ Res. 79:940–948. 1996. View Article : Google Scholar : PubMed/NCBI
11	Wang YW, He SJ, Feng X, Cheng J, Luo YT, Tian L and Huang Q: Metformin: A review of its potential indications. Drug Des Devel Ther. 11:2421–2429. 2017. View Article : Google Scholar : PubMed/NCBI
12	Nicholls SJ, Tuzcu EM, Kalidindi S, Wolski K, Moon KW, Sipahi I, Schoenhagen P and Nissen SE: Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: A pooled analysis of 5 intravascular ultrasound trials. J Am Coll Cardiol. 52:255–262. 2008. View Article : Google Scholar : PubMed/NCBI
13	Norhammar A, Lindbäck J, Rydén L, Wallentin L and Stenestrand U; Register of Information and Knowledge about Swedish Heart Intensive Care Admission (RIKS-HIA), : Improved but still high short- and long-term mortality rates after myocardial infarction in patients with diabetes mellitus: A time-trend report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission. Heart. 93:1577–1583. 2007. View Article : Google Scholar : PubMed/NCBI
14	Wang X, Yang L, Kang L, Li J, Yang L, Zhang J, Liu J, Zhu M, Zhang Q, Shen Y, et al: Metformin attenuates myocardial ischemia-reperfusion injury via up-regulation of antioxidant enzymes. PLoS One. 12:e01827772017. View Article : Google Scholar : PubMed/NCBI
15	Calvert JW, Gundewar S, Jha S, Greer JJ, Bestermann WH, Tian R and Lefer DJ: Acute metformin therapy confers cardioprotection against myocardial infarction via AMPK-eNOS-mediated signaling. Diabetes. 57:696–705. 2008. View Article : Google Scholar : PubMed/NCBI
16	Paiva M, Riksen NP, Davidson SM, Hausenloy DJ, Monteiro P, Gonçalves L, Providência L, Rongen GA, Smits P, Mocanu MM, et al: Metformin prevents myocardial reperfusion injury by activating the adenosine receptor. J Cardiovasc Pharmacol. 53:373–378. 2009. View Article : Google Scholar : PubMed/NCBI
17	Solskov L, Løfgren B, Kristiansen SB, Jessen N, Pold R, Nielsen TT, Bøtker HE, Schmitz O and Lund S: Metformin induces cardioprotection against ischaemia/reperfusion injury in the rat heart 24 hours after administration. Basic Clin Pharmacol Toxicol. 103:82–87. 2008. View Article : Google Scholar : PubMed/NCBI
18	Melendez GC, Chen Q and Lesnefsky EJ: Metformin as a modulator of myocardial fibrosis post-myocardial infarction via regulation of cardiomyocyte-fibroblast crosstalk. Transl Res. 199:1–3. 2018. View Article : Google Scholar : PubMed/NCBI
19	Bai J, Zhang N, Hua Y, Wang B, Ling L, Ferro A and Xu B: Metformin inhibits angiotensin II-induced differentiation of cardiac fibroblasts into myofibroblasts. PLoS One. 8:e721202013. View Article : Google Scholar : PubMed/NCBI
20	Eid AA, Ford BM, Block K, Kasinath BS, Gorin Y, Ghosh-Choudhury G, Barnes JL and Abboud HE: AMP-activated protein kinase (AMPK) negatively regulates Nox4-dependent activation of p53 and epithelial cell apoptosis in diabetes. J Biol Chem. 285:37503–37512. 2010. View Article : Google Scholar : PubMed/NCBI
21	Zhang WX, Tai GJ, Li XX and Xu M: Inhibition of neointima hyperplasia by the combined therapy of linagliptin and metformin via AMPK/Nox4 signaling in diabetic rats. Free Radic Biol Med. 143:153–163. 2019. View Article : Google Scholar : PubMed/NCBI
22	National Research Council, . Guide for the Care and Use of Laboratory Animals. National Academy Press; Washington, DC: 1985
23	Lee SY, Ku HC, Kuo YH, Chiu HL and Su MJ: Pyrrolidinyl caffeamide against ischemia/reperfusion injury in cardiomyocytes through AMPK/AKT pathways. J Biomed Sci. 22:182015. View Article : Google Scholar : PubMed/NCBI
24	Cheng Y, Zhu P, Yang J, Liu X, Dong S, Wang X, Chun B, Zhuang J and Zhang C: Ischaemic preconditioning-regulated miR-21 protects heart against ischaemia/reperfusion injury via anti-apoptosis through its target PDCD4. Cardiovasc Res. 87:431–439. 2010. View Article : Google Scholar : PubMed/NCBI
25	Sun HY, Wang NP, Kerendi F, Halkos M, Kin H, Guyton RA, Vinten-Johansen J and Zhao ZQ: Hypoxic postconditioning reduces cardiomyocyte loss by inhibiting ROS generation and intracellular Ca²⁺ overload. Am J Physiol Heart Circ Physiol. 288:H1900–H1908. 2005. View Article : Google Scholar : PubMed/NCBI
26	Kobashigawa LC, Xu YC, Padbury JF, Tseng YT and Yano N: Metformin protects cardiomyocyte from doxorubicin induced cytotoxicity through an AMP-activated protein kinase dependent signaling pathway: An in vitro study. PLoS One. 9:e1048882014. View Article : Google Scholar : PubMed/NCBI
27	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
28	Poli G and Schaur JR: 4Hydroxynonenal in the pathomechanisms of oxidative stress. IUBMB Life. 50:315–321. 2000. View Article : Google Scholar : PubMed/NCBI
29	Ibáñez B, Heusch G, Ovize M and Van de Werf F: Evolving therapies for myocardial ischemia/reperfusion injury. J Am Coll Cardiol. 65:1454–1471. 2015. View Article : Google Scholar : PubMed/NCBI
30	Sluijter JP, Condorelli G, Davidson SM, Engel FB, Ferdinandy P, Hausenloy DJ, Lecour S, Madonna R, Ovize M, Ruiz-Meana M, et al Nucleus of the European Society of Cardiology Working Group Cellular Biology of the Heart, : Novel therapeutic strategies for cardioprotection. Pharmacol Ther. 144:60–70. 2014. View Article : Google Scholar : PubMed/NCBI
31	Hadi NR, Al-Amran F, Yousif M and Zamil ST: Antiapoptotic effect of simvastatin ameliorates myocardial ischemia/reperfusion injury. ISRN Pharmacol. 2013:8150942013. View Article : Google Scholar : PubMed/NCBI
32	Group UPDS; UK Prospective Diabetes Study (UKPDS) Group, : Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 352:854–865. 1998. View Article : Google Scholar : PubMed/NCBI
33	Schramm TK, Gislason GH, Vaag A, Rasmussen JN, Folke F, Hansen ML, Fosbøl EL, Køber L, Norgaard ML, Madsen M, et al: Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: A nationwide study. Eur Heart J. 32:1900–1908. 2011. View Article : Google Scholar : PubMed/NCBI
34	Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM and Krumholz HM: Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: An observational study. Circulation. 111:583–590. 2005. View Article : Google Scholar : PubMed/NCBI
35	Bedard K and Krause KH: The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 87:245–313. 2007. View Article : Google Scholar : PubMed/NCBI
36	Sato N, Takasaka N, Yoshida M, Tsubouchi K, Minagawa S, Araya J, Saito N, Fujita Y, Kurita Y, Kobayashi K, et al: Metformin attenuates lung fibrosis development via NOX4 suppression. Respir Res. 17:1072016. View Article : Google Scholar : PubMed/NCBI
37	Murdoch CE, Grieve DJ, Cave AC, Looi YH and Shah AM: NADPH oxidase and heart failure. Curr Opin Pharmacol. 6:148–153. 2006. View Article : Google Scholar : PubMed/NCBI
38	Sirker A, Zhang M and Shah AM: NADPH oxidases in cardiovascular disease: Insights from in vivo models and clinical studies. Basic Res Cardiol. 106:735–747. 2011. View Article : Google Scholar : PubMed/NCBI
39	Cheng F, Yuan W, Cao M, Chen R, Wu X, Yan J and Cyclophilin A: Cyclophilin a protects cardiomyocytes against hypoxia/reoxygenation-induced apoptosis via the AKT/Nox2 pathway. Oxid Med Cell Longev. 2019:27179862019. View Article : Google Scholar : PubMed/NCBI
40	Jin Q, Jiang Y, Fu L, Zheng Y, Ding Y and Liu Q: Wenxin granule ameliorates hypoxia/reoxygenation-induced oxidative stress in mitochondria via the PKC-δ/NOX2/ROS pathway in H9c2 cells. Oxid Med Cell Longev. 2020:32454832020. View Article : Google Scholar : PubMed/NCBI
41	Martyn KD, Frederick LM, von Loehneysen K, Dinauer MC and Knaus UG: Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases. Cell Signal. 18:69–82. 2006. View Article : Google Scholar : PubMed/NCBI